OXIGENE INC. (OXGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OXIGENE INC. (OXGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (239)	8/20/2001 7:29:28 PM
From: Miljenko Zuanic	Read Replies (1) of 273

<<Announced 11 minutes before the event? Great news management...>> They are so thirsty for though question! <g> My impression on CC: <<- There have been NO drug related fatalities>> How about cardiac or trombotic event? <<- BMS's P1 trials are ongoing & open for recruitment; have not been halted by the FDA.>> What about modified by FDA, or on suggestion of the SMB? Or modified by BMS? <<- As for time taken over P1 trials, they repeatedly stressed that they are able to monitor drug activity (by monitoring tumor blood flow) as well as toxicity during P1 trials. They suggested that this will give BMS sufficient data to be able to conduct quicker P11 trials.>> Seams to me that BMS are applying special technique primarily for monitoring drug side effects (CA4P interaction with normal vasculature/tubulin), than for tumor activity. Anyway, BMS will need two years to correct and fix what OXGN was done wrong in their 100 pts three PI trials. At the end (my speculation) they may have safe but an-effective dose. CA4P may be a good drug to STUDY (fast and short action, irreversible one) tubulin targeting agent, which may be only BMS attention at this time. And OXGN will never found what went wrong? Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next